Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Inclusion Criteria:

- Best corrected visual acuity (ETDRS scale) of 60 letters or less in the study eye.

- An active choroidal neovascular membrane attributable to neovascular AMD in at least
one eye.

- History of treatment (at any time) with at least 3 doses of anti-VEGF therapy in the
study eye.

Exclusion Criteria:

- History of recurrent non-response to anti-VEGF therapy in the study eye.

- In the study eye, retinal disease other than AMD (benign conditions of the vitreous
and peripheral retina are not exclusionary).

- Choroidal neovascularization due to a cause other than AMD.

- In the study eye, media opacity that, in the investigator's opinion, could interfere
with conduct of the study.

- History of infectious uveitis or endophthalmitis in either eye.

- Any of the following treatments to the study eye within 28 days prior to dosing:
ranibizumab, bevacizumab, pegaptanib or other VEGF inhibitor.

- Any of the following within 90 days prior to dosing: photodynamic therapy or laser
photocoagulation in the study eye; intravitreal steroid in the study eye; or
intraocular surgery (including cataract surgery) in the study eye